Erectile Dysfunction - Pipeline Review, H2 2016

Date: July 30, 2016
Pages: 108
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: EE05B3281FCEN
Leaflet:

Download PDF Leaflet

Erectile Dysfunction - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Erectile Dysfunction - Pipeline Review, H2 2016’, provides an overview of the Erectile Dysfunction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Erectile Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction
  • The report reviews pipeline therapeutics for Erectile Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Erectile Dysfunction therapeutics and enlists all their major and minor projects
  • The report assesses Erectile Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Erectile Dysfunction
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Erectile Dysfunction
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Erectile Dysfunction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Erectile Dysfunction Overview
Therapeutics Development
Pipeline Products for Erectile Dysfunction - Overview
Pipeline Products for Erectile Dysfunction - Comparative Analysis
Erectile Dysfunction - Therapeutics under Development by Companies
Erectile Dysfunction - Therapeutics under Investigation by Universities/Institutes
Erectile Dysfunction - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Erectile Dysfunction - Products under Development by Companies
Erectile Dysfunction - Products under Investigation by Universities/Institutes
Erectile Dysfunction - Companies Involved in Therapeutics Development
Apricus Biosciences, Inc.
Aytu BioScience, Inc.
Biopharm GmbH
Futura Medical Plc
Hanmi Pharmaceuticals, Co. Ltd.
Humanetics Corporation
IntelGenx Corp.
Ion Channel Innovations, LLC
Mezzion Pharma Co. Ltd.
Mitsubishi Tanabe Pharma Corporation
Monosol Rx, LLC
NAL Pharmaceuticals Ltd.
Palatin Technologies, Inc.
Pharmicell Co., Ltd.
Sihuan Pharmaceutical Holdings Group Ltd.
Suda Ltd
Yungjin Pharm. Co., Ltd.
Erectile Dysfunction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(PDE-5 Inhibitor + tramadol hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alprostadil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avanafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BL-214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellgram-ED - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fadanafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HCP-1302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HCP-1303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MED-2002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MED-2005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pVAX-hSlo - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUD-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-6932 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TF-0092 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPN-729 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TR-399 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
udenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VLFIA-330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YBH-1603 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Erectile Dysfunction - Dormant Projects
Erectile Dysfunction - Discontinued Products
Erectile Dysfunction - Product Development Milestones
Featured News & Press Releases
Mar 28, 2016: MonoSol Rx Successfully Completes Pre-IND Meeting with the FDA for PharmFilm Tadalafil
Nov 25, 2015: iX Biopharma Announces Success Of Pilot Bioavailability Study For Pheonix
Jan 29, 2015: VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity
Nov 20, 2014: Auxilium Pharmaceuticals Presents STENDRA Data At SMSNA Scientific Meeting
Nov 03, 2014: Auxilium Pharmaceuticals To Present STENDRA Data At SMSNA Scientific Meeting
Sep 18, 2014: VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity
Jul 09, 2014: New Grant Enables Humanetics to Evaluate Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients
Apr 11, 2014: VIVUS To Present Clinical Data On Avanafil at European Association of Urology
Feb 24, 2014: IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm Tadalafil Product
Jan 21, 2014: VIVUS and Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing Information for STENDRA (avanafil)
Aug 01, 2013: VIVUS Announces Commercial Supply Agreement With Sanofi to Produce Avanafil
Jun 26, 2013: Vivus Announces European Approval For Spedra For Treatment Of Erectile Dysfunction
Jun 19, 2013: Vivus Announces Positive Results From TA-501 Clinical Trial Of Stendra For Treatment Of Men With Erectile Dysfunction
Apr 25, 2013: Vivus Receives CHMP Positive Opinion For Spedra For Treatment Of Erectile Dysfunction In Adult Men
Jul 18, 2012: Zydus Urosciences Launches Udenafil For Treatment Of Erectile Dysfunction In India
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Erectile Dysfunction, H2 2016
Number of Products under Development for Erectile Dysfunction - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Erectile Dysfunction - Pipeline by Apricus Biosciences, Inc., H2 2016
Erectile Dysfunction - Pipeline by Aytu BioScience, Inc., H2 2016
Erectile Dysfunction - Pipeline by Biopharm GmbH, H2 2016
Erectile Dysfunction - Pipeline by Futura Medical Plc, H2 2016
Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
Erectile Dysfunction - Pipeline by Humanetics Corporation, H2 2016
Erectile Dysfunction - Pipeline by IntelGenx Corp., H2 2016
Erectile Dysfunction - Pipeline by Ion Channel Innovations, LLC, H2 2016
Erectile Dysfunction - Pipeline by Mezzion Pharma Co. Ltd., H2 2016
Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
Erectile Dysfunction - Pipeline by Monosol Rx, LLC, H2 2016
Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd., H2 2016
Erectile Dysfunction - Pipeline by Palatin Technologies, Inc., H2 2016
Erectile Dysfunction - Pipeline by Pharmicell Co., Ltd., H2 2016
Erectile Dysfunction - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2016
Erectile Dysfunction - Pipeline by Suda Ltd, H2 2016
Erectile Dysfunction - Pipeline by Yungjin Pharm. Co., Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Erectile Dysfunction - Dormant Projects, H2 2016
Erectile Dysfunction - Dormant Projects (Contd..1), H2 2016
Erectile Dysfunction - Dormant Projects (Contd..2), H2 2016
Erectile Dysfunction - Dormant Projects (Contd..3), H2 2016
Erectile Dysfunction - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Erectile Dysfunction, H2 2016
Number of Products under Development for Erectile Dysfunction - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Left Ventricular Dysfunction - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 60 pages
Left Ventricular Dysfunction - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 56 pages
Endothelial Dysfunction - Pipeline Review, H1 2014 US$ 1,500.00 May, 2014 · 40 pages
Endothelial Dysfunction - Pipeline Review, H2 2014 US$ 1,600.00 Nov, 2014 · 32 pages
Erectile Dysfunction - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages

Ask Your Question

Erectile Dysfunction - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: